Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our Spain, Italy, USA, China, France, Belgium, Canada, South Korea, Germany, India, Netherlands, Portugal, Turkey, Denmark, Japan, Taiwan, Singapore, Australia, UK, Austria, Brazil and Mexico registers that name Opnurasib as an intervention.Synced 1 Oct 2026
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards
At a glance
Opnurasib is named as an intervention in 6 current clinical trials
in our Spain, Italy, USA, China, France, Belgium, Canada, South Korea, Germany, India, Netherlands, Portugal, Turkey, Denmark, Japan, Taiwan, Singapore, Australia, UK, Austria, Brazil and Mexico registers.
1 is recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Novartis Pharmaceuticals (5). The most-studied condition is KRAS G12C Mutant Solid Tumors.
Diseases it has been tested for in clinical trials, by furthest phase
Non-small cell lung carcinomaPhase 3
Mechanism, targets and diseases from ChEMBL via the Open Targets Platform (release 26.09), matched to this page as ChEMBL record CHEMBL5077861. ChEMBL data is licensed CC BY-SA 3.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NCT05445843 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
02
Conditions studied with Opnurasib
10 conditions
KRAS G12C Mutant Solid Tumors2Carcinoma, Non-Small-Cell Lung2Non-Small Cell Lung Cancer2Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation1Carcinoma, Colorectal1Cancer of Lung1Carcinoma, Non-Small Cell Lung1Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer1Advanced Solid Tumors Harboring the KRAS G12C Mutation1NSCLC1
6 current trials in our Spain, Italy, USA, China, France, Belgium, Canada, South Korea, Germany, India, Netherlands, Portugal, Turkey, Denmark, Japan, Taiwan, Singapore, Australia, UK, Austria, Brazil and Mexico registers name Opnurasib (also registered as JDQ443) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Are Opnurasib trials recruiting patients?
Yes. 1 of the 6 trials is recruiting: 1 with sites in Spain, 1 with sites in Italy, 1 with sites in China, 1 with sites in France, 1 with sites in Belgium, 1 with sites in Canada, 1 with sites in South Korea, 1 with sites in Denmark and 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Opnurasib clinical trials?
Novartis Pharmaceuticals (5) and Canadian Cancer Trials Group (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Opnurasib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Opnurasib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Opnurasib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
Please verify before you rely on this.
This page is general information for life-science and pharmaceutical professionals. It is
not medical advice, and it has not been reviewed by a clinician — our editorial
team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most
recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC)
and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not
automatically interchangeable, and approvals, brand names and indications differ between the US, the
EU/Ireland (EMA/HPRA) and other regions.
Spotted an error? Tell us — we correct promptly and log it.
We value your privacy
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.